Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine

References

• World Health Organization. Hepatitis B vaccines. Wkly Epidemiol Rec 2009; 84:405 - 19; PMID: 19817017
   PubMedGoogle Scholar
• André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989; 87:Suppl 3a 14S - 20S; http://dx.doi.org/10.1016/0002-9343(89)90525-1; PMID: 2528292
   PubMed Web of Science ®Google Scholar
• Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989; 160:766 - 9; http://dx.doi.org/10.1093/infdis/160.5.766; PMID: 2530289
   PubMed Web of Science ®Google Scholar
• Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: Saunders, 1999:158–82.
   Google Scholar
• Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective?. J Infect Dis 1999; 179:489 - 92; http://dx.doi.org/10.1086/314578; PMID: 9878036
   PubMed Web of Science ®Google Scholar
• Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Infect Dis Clin North Am 2006; 20:27 - 45; http://dx.doi.org/10.1016/j.idc.2006.01.004; PMID: 16527647
   PubMedGoogle Scholar
• Cardell K, Åkerlind B, Sällberg M, Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 2008; 198:299 - 304; http://dx.doi.org/10.1086/589722; PMID: 18544037
   PubMed Web of Science ®Google Scholar
• Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989; 87:3A 36S - 40S; http://dx.doi.org/10.1016/0002-9343(89)90530-5; PMID: 2528297
   PubMed Web of Science ®Google Scholar
• Höhler T, Reuss E, Evers N, Dietrich E, Rittner C, Freitag CM, et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 2002; 360:991 - 5; http://dx.doi.org/10.1016/S0140-6736(02)11083-X; PMID: 12383669
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommended adult immunization schedule — United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61; PMID: 22298301
   PubMedGoogle Scholar
• Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209 - 14; http://dx.doi.org/10.1056/NEJM198607243150401; PMID: 2941687
   PubMed Web of Science ®Google Scholar
• Jacques P, Moens G, Desombere I, Dewijngaert J, Leroux-Roels G, Wettendorff M, et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002; 20:3644 - 9; http://dx.doi.org/10.1016/S0264-410X(02)00397-3; PMID: 12399191
   PubMed Web of Science ®Google Scholar
• Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rümke H, Boland G, et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006; 24:2781 - 9; http://dx.doi.org/10.1016/j.vaccine.2006.01.007; PMID: 16455169
   PubMed Web of Science ®Google Scholar
• Goldwater PN. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997; 15:353 - 6; http://dx.doi.org/10.1016/S0264-410X(96)00202-2; PMID: 9141204
   PubMedGoogle Scholar
• Lin C, Zhu J, Zheng Y, Chen Y, Wu Z, Chong Y, et al. Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders. J Infect 2010; 60:264 - 70; http://dx.doi.org/10.1016/j.jinf.2010.01.011; PMID: 20138189
   PubMed Web of Science ®Google Scholar
• Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 2003; 21:4604 - 8; http://dx.doi.org/10.1016/S0264-410X(03)00447-X; PMID: 14575774
   PubMed Web of Science ®Google Scholar
• Zuckerman JN, Zuckerman AJ, Symington I, Du W, Williams A, Dickson B, et al, UK Hepacare Study Group. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology 2001; 34:798 - 802; http://dx.doi.org/10.1053/jhep.2001.27564; PMID: 11584378
   PubMedGoogle Scholar
• Hoebe CJ, Vermeiren AP, Dukers-Muijrers NH. Revaccination with Fendrix® or HBVaxPro® results in better response rates than does revaccination with three doses of Engerix-B® in previous non-responders. Vaccine 2012; 30:6734 - 7; http://dx.doi.org/10.1016/j.vaccine.2012.08.074; PMID: 22981848
   PubMed Web of Science ®Google Scholar
• Pisetsky DS. Immune activation by bacterial DNA: a new genetic code. Immunity 1996; 5:303 - 10; http://dx.doi.org/10.1016/S1074-7613(00)80256-3; PMID: 8885863
   PubMed Web of Science ®Google Scholar
• Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321:209 - 13; http://dx.doi.org/10.1038/321209a0; PMID: 2423876
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492 - 503; http://dx.doi.org/10.1016/j.immuni.2010.10.002; PMID: 21029960
   PubMed Web of Science ®Google Scholar
• Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003; 21:2461 - 7; http://dx.doi.org/10.1016/S0264-410X(03)00045-8; PMID: 12744879
   PubMed Web of Science ®Google Scholar
• Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006; 24:20 - 6; http://dx.doi.org/10.1016/j.vaccine.2005.08.095; PMID: 16198027
   PubMed Web of Science ®Google Scholar
• Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine 2012; 30:2556 - 63; http://dx.doi.org/10.1016/j.vaccine.2012.01.087; PMID: 22326642
   PubMed Web of Science ®Google Scholar
• Halperin SA, McNeil S, Langley JM, Smith B, MacKinnon-Cameron D, McCall-Sani R, et al. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults. Vaccine 2012; 30:5445 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.05.074; PMID: 22704926
   PubMed Web of Science ®Google Scholar
• Clemens R, Sänger R, Kruppenbacher J, Höbel W, Stanbury W, Bock HL, et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule—results of a post-marketing surveillance. Vaccine 1997; 15:349 - 52; http://dx.doi.org/10.1016/S0264-410X(96)00205-8; PMID: 9141203
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12:1204 - 11; http://dx.doi.org/10.1093/ndt/12.6.1204; PMID: 9198052
   PubMed Web of Science ®Google Scholar
• Valats JC, Tuaillon E, Funakoshi N, Hoa D, Brabet MC, Bolloré K, et al. Investigation of memory B cell responses to hepatitis B surface antigen in health care workers considered as non-responders to vaccination. Vaccine 2010; 28:6411 - 6; http://dx.doi.org/10.1016/j.vaccine.2010.07.058; PMID: 20682363
   PubMedGoogle Scholar
• Chen J, Liang Z, Lu F, Fang X, Liu S, Zeng Y, et al. Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine. Vaccine 2011; 29:706 - 11; http://dx.doi.org/10.1016/j.vaccine.2010.11.023; PMID: 21111021
   PubMed Web of Science ®Google Scholar
• Velu V, Saravanan S, Nandakumar S, Shankar EM, Vengatesan A, Jadhav SS, et al. Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines. World J Gastroenterol 2008; 14:3534 - 40; http://dx.doi.org/10.3748/wjg.14.3534; PMID: 18567083
   PubMed Web of Science ®Google Scholar
• Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994; 344:856 - 7; http://dx.doi.org/10.1016/S0140-6736(94)92829-0; PMID: 7916403
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546 - 9; http://dx.doi.org/10.1038/374546a0; PMID: 7700380
   PubMed Web of Science ®Google Scholar
• Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996; 93:2879 - 83; http://dx.doi.org/10.1073/pnas.93.7.2879; PMID: 8610135
   PubMed Web of Science ®Google Scholar
• Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3:849 - 54; http://dx.doi.org/10.1038/nm0897-849; PMID: 9256274
   PubMed Web of Science ®Google Scholar
• Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, Werner BG, et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 1986; 105:356 - 60; PMID: 2943202
   PubMed Web of Science ®Google Scholar
• Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 321:708 - 12; http://dx.doi.org/10.1056/NEJM198909143211103; PMID: 2528067
   PubMed Web of Science ®Google Scholar
• Hsu HY, Chang MH, Ho HN, Hsieh RP, Lee SD, Chen DS, et al. Association of HLA-DR14-DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. Vaccine 1993; 11:1437 - 40; http://dx.doi.org/10.1016/0264-410X(93)90173-U; PMID: 8310763
   PubMed Web of Science ®Google Scholar
• Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 1998; 51:593 - 604; http://dx.doi.org/10.1111/j.1399-0039.1998.tb03001.x; PMID: 9694351
   PubMed Web of Science ®Google Scholar
• McDermott AB, Zuckerman JN, Sabin CA, Marsh SG, Madrigal JA. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens 1997; 50:8 - 14; http://dx.doi.org/10.1111/j.1399-0039.1997.tb02827.x; PMID: 9243749
   PubMedGoogle Scholar